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A PROVIDER’S GUIDE TO
MEDICAL CANNABIS:
THC AND CBD
Putting the Evidence to Work for Improved Patient Care
Danielle Smith, MS3
UVMMC Family Medicine: South Burlington
Family Medicine Rotation 6, January 2019

PROBLEM IDENTIFICATION
• An estimated 50 million Americans or 20% of adults in the US have chronic pain. An
additional 19.6 million Americans have high-impact chronic pain11

• Chronic pain is reported at higher rates among adults who are women, older than 65
years of age, unemployed, living in poverty, insured with public health insurance,
and residents of rural areas11

• According to the Anxiety and Depression Association of American, 40 million adults
in the US, or 18%, suffer from anxiety. Anxiety disorders are the most common mental
illness in the US12
• Problems with falling asleep or daytime sleepiness affect approximately 35 to 40% of
the U.S. adult population annually and are a significant cause of morbidity and
mortality13
• As of March 2018, there were 5,571 patients enrolled in the Vermont Marijuana
Registry. Qualifying conditions include cancer, multiple sclerosis, positive status for
human immunodeficiency virus, acquired immune deficiency syndrome, glaucoma,
Crohn’s disease, Parkinson’s disease, and other conditions causing intractable
symptoms.14

PROBLEM IDENTIFICATION
CONTINUED
• In 2017, an ad hoc committee of the National Academies of Science,
Engineering, and Medicine published the report The Health Effects of
Cannabis and Cannabinoids: The Current State of Evidence and
Recommendations for Research. In the report, the committee presented
nearly 100 conclusions related to the health effects of medical cannabis.
Some of their conclusions include:
• There is conclusive or substantial evidence that cannabis or cannabinoids are
effective for the treatment of chronic pain in adults
• There is moderate evidence that cannabis or cannabinoids are effective for
improving short term sleep outcomes in individuals with sleep disturbance
associated with sleep apnea syndrome, fibromyalgia, chronic pain, and multiple
sclerosis
• There is limited evidence that cannabis or cannabinoids are effective for
improving anxiety symptoms and symptoms of PTSD.

DESCRIPTION OF NEED
• “I have patients ask me about medical marijuana and CBD all the time. I just
don’t know enough about it to feel really comfortable recommending it. It
would be super helpful to have more information about potentially using
medical cannabis as an alternative to less desirable medications for things
like pain and insomnia” – Robert Luebbers, MD
• The number of opioid related fatalities has continued to rise with 33% of
opioid related deaths in 2017 caused by prescription opiates.15
• 62% of Vermonters using medical cannabis have chronic pain.16
• 28.2% of Vermonters using medical cannabis have been diagnosed with an
anxiety disorder.16
• 22.5% of Vermonters using medical cannabis have been diagnosed with
insomnia or another sleep disorder.16

PUBLIC HEALTH
COSTS
• The total cost of pain to society
combining healthcare cost
estimates and three productivity
estimates ranges from $560 - $635
billion dollars annually.17

• Insufficient sleep costs $411 billion
dollars annually, 2.28% of the United
States GDP.18
• Federally, medical cannabis is
considered a Schedule 1
substance. In Vermont, state
legislature legalized the use of
homegrown and medical cannabis.
Because of this discrepancy, data
on the public health costs of
medical cannabis use is lacking.

Hafner et al. 2017

COMMUNITY PERSPECTIVE
AND SUPPORT #1
• My first community interview took place with Ada Puches, the Community Outreach
Coordinator for Champlain Valley Dispensaries and Southern Vermont Wellness. Ms.
Puches provided me with a folder full of resources highlighting the scientific
evidence behind the use of medical cannabis. She was extremely excited to learn
about the project to help medical providers learn more about her field. She
instructed me on the requirements for qualifying conditions for medical marijuana by
Vermont State Law and educated me regarding the regulations faced by
dispensaries in Vermont. She also helped me learn about the routes of administration
of varying medical cannabis products and how the different products can be useful
for different chief complaints.
• “I love working in the field of medical cannabis because I have so much opportunity
to help people. Most of my clients are using medical cannabis for pain, but a large
portion of them use our products for help with sleep. Medical cannabis is so much
safer than [for example] fentanyl patches and I’m glad that health care providers
are interested in learning more.
• -Ada Puches, Community Outreach Coordinator, Champlain Valley Dispensaries

COMMUNITY PERSPECTIVE
AND SUPPORT #2
• My second community interview was with Paul Jerard, PA-C who runs the Vermont
Cannabinoid Clinic providing medical guidance for medicinal cannabis. Mr. Jerard
started working in the field of medical cannabis after speaking with some friends in
Colorado who were doing similar advising. He realized that there was a need in
Vermont for medical guidance and support for providers, so he started the Vermont
Cannabinoid Clinic. Mr. Jerard was instrumental to my understanding of the
pharmacology, adverse effects, and dosing suggestions for both THC and CBD
products. He receives consults from other health care providers in order to help their
patients manage their chronic conditions with medical cannabis. Most of his
patients have several chronic conditions and are interested in exploring cannabis as
an alternative therapy to more traditional allopathic medications.

• “The type of cannabis that I usually suggest for most people is the cannabis with THC
and CBD in a 1:1 ratio. CBD augments the psychoactive effects of THC and keeps
people from feeling as high. You also get the anti-inflammatory effects from the CBD.
It’s important to start at a low dose and titrate up. Start with 2mg of THC and
increase the dose by 0.5mg every 2-3 days until symptoms have improved
• -Paul Jerard, PA-C, Vermont Cannabinoid Clinic

INTERVENTION AND METHODOLOGY
• I constructed an educational handout for medical providers discussing the scientific
evidence behind the therapeutic effects of medical cannabis focusing on THC and
CBD. The handout includes information on pharmacology, drug interactions,
contraindications, adverse effects, routes of administration, and dosing
recommendations for THC, CBD, and THC/CBD combinations. I also included
information specific to ensuring that patients could purchase high quality CBD-rich
oils from respected sources.
• A two question before handout survey was administered to 6 providers prior to their
reviewing the handout. After the providers reviewed the handout, they completed
an additional two question after handout survey to assess for the effectiveness of the
handout.
• All 6 providers where medical doctors working at the UVMMC Family Medicine Clinic
in South Burlington
• Before and after data were then plotted.

RESULTS AND
PROVIDER
RESPONSE
• Response to the handout was
positive!
• Comfort level with
recommending medical
cannabis increased by 2 points
after providers reviewed the
handout
• Likelihood of recommending
medical cannabis increased by
1.8 points after providers
reviewed the handout
• 100% of providers said they
would use the information from
the handout in their future
practice
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EVALUATION OF EFFECTIVENESS
AND LIMITATIONS

• Based on my preliminary results, I can conclude that my handout was effective at
increasing provider confidence and liklihood in recommending medical cannabis as
therapeutic intervention for evidence based indications.
• Anecdotally, many providers in Vermont would like to find an effective alternative to
prescribing medications like opiates and benzodiazepines for chronic pain and anxiety,
respectively. I can conclude that my intervention was effective at increasing provider
knowledge base given the 100% provider response that they will use the information in
their future practice.
• My current sample size for evaluation of effectiveness is small. Increasing the sample size
would increase the power of the study and increase confidence in the effectiveness of
the handout.
• Limitations:
• Small sample size – 6 providers were surveyed
• Current legislation and regulations do not provide adequate assurance that THC or CBD
products contain what is advertised on the label. Quality control is currently regulated by the
state for medical marijuana and is not regulated at all for CBD. Providers have to ensure that
patients are aware of the possibility of failed drug testing while using medical cannabis
products.
• There was not enough time during the 6 week family medicine clerkship to evaluate the future
implications of increased provider education on this topic.

RECOMMENDATIONS FOR FUTURE
INTERVENTIONS AND PROJECTS
• Increase distribution of the hand out among family medicine providers in the
UVM Health Network
• Distribute the handout to other providers not associated with Family
Medicine. Providers in every field of medicine will care for patient with
chronic pain, anxiety, sleep issues, etc.
• Future medical students can track the number of times that providers
recommend medical cannabis to their patients for conditions backed by
scientific evidence. If the number of recommendations increases, it is likely
that this is secondary to increased knowledge gained from the handout.
• The field of medical cannabis is a burgeoning field of research with new
evidence published daily. A future medical student could update the
handout based on the most up to date information annually following
publishing of new high quality evidence.
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CONSENT FOR INTERVIEWS
• Thank you for agreeing to be interviewed. This project is a requirement for
the Family Medicine clerkship. It will be stored on the Dana Library
ScholarWorks website. Your name will be attached to your interview and you
may be cited directly or indirectly in subsequent unpublished or published
work. The interviewer affirms that he/she has explained the nature and
purpose of this project. The interviewee affirms that he/she has consented to
this interview. Yes __x___ / No _____ If not consenting as above: please add
the interviewee names here for the department of Family Medicine
information only. Name: __Ada Puches, Community Outreach Coordinator,
Champlain Valley Dispensary
• Name: Paul Jerard, PA-C, Vermont Cannabinoid Clinic

